[Kim Jinsoo, Edaily Reporter] Investors in the biopharmaceutical sector continued to show strong interest in BL Pharmtech on July 2, driving its stock to the daily upper limit. The surge was fueled by growing expectations of tangible results on the global stage. Raphas also saw a significant increase following its announcement the previous day of a partnership with a leading global advanced materials company.

Meanwhile, Samchundang Pharm shares fell nearly 9% following news that the Financial Supervisory Service (FSS) is investigating the company for potential violations of its disclosure obligations.

BL Pharmtech Hits Daily Upper Limit on Tangible Results

According to KG Zeroin MP Doctor, BL Pharmtech’s stock showed strength from the opening bell. It reached the daily limit in the afternoon, closing at 3,535 won, up 815 won from the previous day’s close. The stock has been on an upward trend for about 10 days, surging approximately 118% from its June 22 close of 1,632 won.

The recent surge is attributed to global interest and expectations surrounding its molecular glue platform technology and its applied pipeline, “ML301.”

BL Pharmtech announced that it had established partnerships with global pharmaceutical companies and investment firms at the recent BIO International Convention 2026 (BIO USA). It also signed non-disclosure agreements (NDAs) and agreed to share follow-up data with multiple global companies.

Specifically, the chief scientific officer and head of business development at a global pharmaceutical company currently supporting BL Pharmtech’s technology development gave a positive assessment of the potential for out-licensing the preclinical and early clinical pipeline. The two companies plan to discuss development progress and follow-up cooperation plans at the U.S. headquarters in October.

Furthermore, the head of business development at a global biotech company specializing in anticancer drugs expressed strong interest in BL Pharmtech’s molecular glue-based anticancer project. The two parties agreed to share confidential data after signing an NDA and will conduct an in-depth review to assess the potential for technology adoption.

A French pharmaceutical company recognized the potential of developing BL Pharmtech’s anticancer candidate as a small-molecule treatment for brain tumors. The two parties agreed to share development status and research data after signing a non-disclosure agreement (NDA), with an eye toward technology export.

The company also achieved results in strategic consulting and investment networking to facilitate its entry into the global market. A U.S. firm specializing in drug development incubation and business development consulting decided to actively support maximizing the value of BL Pharmtech’s technology assets and identifying global partners by leveraging its infrastructure and asset-matching services.

In addition, a major U.K. investment firm and global biotech company specializing in anticancer drugs expressed its intention to support the translational research phase prior to clinical trials by leveraging its clinical network in the U.K. After signing a non-disclosure agreement (NDA), the two companies agreed to share detailed data and discuss specific models of cooperation.

“This BIO USA was a meaningful event that confirmed the innovation and global competitiveness of our molecular glue-based anticancer pipeline and early-stage development assets,” said a BL Pharmtech official. “We will do our best to generate tangible business results—such as joint research and early-stage technology exports—by swiftly signing NDAs and sharing research data with the global companies we met.”

Raphas Draws Attention with Hosokawa Micron Partnership

Raphas shares closed at 9,080 won, up 9.27% from the previous day. The rise is attributed to the partnership with Hosokawa Micron announced the previous day.

On July 1, Raphas announced that it would target the cosmetics and pharmaceutical markets based on a next-generation drug delivery system (DDS) in collaboration with Hosokawa Micron, a leading global advanced materials company based in Japan.

Raphas signed a three-party strategic alliance agreement with Hosokawa Micron and its local subsidiary, Raphas Japan, to commercialize the integration of “advanced nanoparticle technology” and “microneedle manufacturing technology.”

Specifically, Raphas plans to integrate Hosokawa Micron’s proprietary “PLGA (poly lactic-co-glycolic acid) nanocomposite encapsulation technology” into its microneedle patch technology. The two companies successfully completed prototype verification earlier this year and have now entered the full-scale commercialization phase.

“Since Hosokawa Micron is relatively unknown in South Korea, the market response seemed somewhat delayed as the company was being evaluated,” said a Raphas official. “The fact that a global materials company like Hosokawa Micron selected Raphas as its exclusive manufacturing and commercialization partner is a result of the market’s official recognition of our microneedle technology’s platform value and production capacity.”

Samchundang Pharm Shares Drop 9% on News of FSS Probe

Samchundang Pharm shares closed at 204,000 won, down 8.72% from the previous day. The decline is believed to have been influenced by news that the Financial Supervisory Service (FSS) has launched a formal investigation into the company.

A news outlet reported the previous day that, following the Korea Exchange’s designation of Samchundang Pharm as a company with inadequate disclosure practices and the imposition of penalty points, the FSS is conducting an intensive investigation into whether the company violated disclosure obligations, such as stating false information in its regulatory filings.

In April, the KOSDAQ Market Division of the Korea Exchange designated Samchundang Pharm as a company with inadequate disclosure practices and imposed five penalty points for “failure to fulfill fair disclosure regarding forecasts or predictions of business performance.”

In response, Samchundang Pharm stated on its website that the “designation as a company with inadequate disclosure is a procedural issue related to fair disclosure” and is unrelated to false disclosures.

According to Samchundang Pharm, the reason for the designation was the penalty points incurred from distributing a press release about the performance of its Eylea biosimilar, “SCD411,” in the Canadian market before going through formal disclosure procedures. The company argued that this was a measure taken for failing to sufficiently fulfill fair disclosure obligations under the Capital Markets Act, not a false disclosure.

Regarding contracts in the U.S. and European markets, the company drew a clear distinction, stating, “This is a completely separate matter from the large-scale overseas contracts mentioned in the report.”

“Our core business and global operations currently underway are proceeding normally without any setbacks,” Samchundang Pharm said. “We will do our best to restore market trust and enhance shareholder value through transparent management and sincere communication.”